Compounded vs Brand Semaglutide: Safety, Legality, and Cost in 2026

Reviewed by Sydney Duong, RD, GLPeak Clinical Lead · Last updated 2026-06-17

Quick answer: The FDA removed semaglutide from the official shortage list, which ended most compounding pharmacies' legal authority to mass-produce it. Compounded semaglutide is not FDA-approved, is not regulated for sterility or potency, and is no longer broadly legal in 2026. Brand Ozempic and Wegovy remain the safest, regulated option — supplemented by NovoCare cash-pay or manufacturer savings cards for cost.

Why compounded semaglutide existed

Federal law lets compounding pharmacies make a non-branded version of a drug while it's on the FDA's official shortage list. Semaglutide was on that list from 2022 through 2024, which is when telehealth clinics shipped compounded vials at a fraction of brand pricing.

Once a drug comes off the shortage list, most compounding stops. Section 503A and 503B pharmacies have a narrow personalization carve-out (a documented clinical reason a specific patient needs a non-standard formulation), but mass-market compounding for cost reasons is no longer allowed.

Safety differences

Cost comparison in 2026

Frequently asked questions

Can my telehealth clinic still ship compounded semaglutide?

Most cannot, as of 2026. A narrow personalization exception exists, but mass-market compounded shipments are largely no longer legal. Confirm any clinic offering it is operating within FDA guidance.

Is compounded tirzepatide the same situation?

Yes — tirzepatide also came off the shortage list, ending most compounding. Eli Lilly now offers self-pay Zepbound vials through LillyDirect as an FDA-approved alternative.

What if I was already on compounded semaglutide?

Talk to a prescriber about transitioning to brand Ozempic, Wegovy, or self-pay Zepbound. Don't abruptly stop a GLP-1 if you're mid-treatment without a plan.

Related GLPeak tools

Educational only — not medical advice. Consult your prescriber before changing any medication.

Open GLPeak →